Yupelri

YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

The recommended dosage is 175 mcg YUPELRI (one 175 mcg unit‑dose vial) administered by oral inhalation once daily by nebulizer using a mouthpiece.

YUPELRI should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor

The YUPELRI unit-dose vial should only be removed from the foil pouch and opened IMMEDIATELY BEFORE USE. The vial and any residual content should be discarded after use.

No dosage adjustment is required for geriatric patients, or patients with renal impairment

The drug compatibility (physical and chemical), efficacy, and safety of YUPELRI when mixed with other drugs in a nebulizer have not been established.

Inhalation solution: 175 mcg of revefenacin in 3 mL of sterile, clear, colorless, aqueous solution in unit dose vials.

Hepatic impairment: Avoid use of YUPELRI in patients with hepatic impairment.

• •Do not initiate YUPELRI in acutely deteriorating COPD or to treat acute symptoms.
• •If paradoxical bronchospasm occurs, discontinue YUPELRI and institute alternative therapy.
• •Worsening of narrow-angle glaucoma may occur. Use with caution in patients with narrow-angle glaucoma and instruct patients to contact a healthcare provider immediately if symptoms occur.
• •Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.
• •Immediate hypersensitivity reactions may occur. If such a reaction occurs, therapy with YUPELRI should be stopped at once and alternative treatments should be considered.